NGM Biopharmaceuticals Inc $ 27.15 0.43 (1.61%)
Volume:
240,439
Avg Vol (1m):
337,412
Market Cap $:
2.02 Bil
Enterprise Value $:
1.73 Bil
PE Ratio:
0.00
PB Ratio:
6.75
Financial Strength | 9/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | No Debt | ||
Equity-to-Asset | 0.85 | ||
Interest Coverage | No Debt | ||
Altman Z-Score | 23.73 | ||
Beneish M-Score | 0 | ||
WACC vs ROIC |
Profitability Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -94.7 | ||
Net Margin % | -91.64 | ||
ROE % | -28.86 | ||
ROA % | -25.05 | ||
ROC (Joel Greenblatt) % | -511.64 | ||
3-Year Revenue Growth Rate | 8.9 | ||
3-Year EBITDA Growth Rate | -109.7 | ||
3-Year EPS without NRI Growth Rate | -87.5 |
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 6.75 | ||
PS Ratio | 18.62 | ||
EV-to-EBIT | -18.53 | ||
EV-to-EBITDA | -19.97 | ||
EV-to-Revenue | 17.54 | ||
Current Ratio | 8.01 | ||
Quick Ratio | 8.01 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -7.7 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 6.75 | ||
Earnings Yield (Greenblatt) % | -5.4 |